Solabegron
CAS: 252920-94-8
Ref. 3D-CKA92094
| 1mg | To inquire | ||
| 2mg | To inquire | ||
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire |
Product Information
- (-)-(R)-3′-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]biphenyl-3-carboxylic acid
- 3′-[[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino][1,1′-biphenyl]-3-carboxylic acid
- Gw 427353
- [1,1′-Biphenyl]-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-
Solabegron is a drug that has clinical relevance for the treatment of bladder disorders. It is an agonist of the beta-3 adrenergic receptor, with no affinity for beta-1 or beta-2 receptors. In animal models, solabegron has been shown to increase detrusor muscle contractility and reduce urinary symptoms. Solabegron also acts as an inhibitor of DPP-IV, which is involved in the breakdown of glucagon-like peptide (GLP). The drug reduces body mass index and improves metabolic disorders in animals by stimulating GLP secretion. Solabegron is metabolized by CYP3A4 and has hydrogen bonding interactions with drugs such as erythromycin, clarithromycin, and telithromycin.
Chemical properties
Technical inquiry about: 3D-CKA92094 Solabegron
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
